TKNO Q3 2025 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$133M

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$10M+9.2% YoY

Gross Profit

$3M30.7% margin

Operating Income

-$4M-38.4% margin

Net Income

-$4M-41.0% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+1.6%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$108M

Total Liabilities

$35M

Stockholders' Equity

$73M

Cash & Equivalents

$3M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$10M	+9.2%
Gross Profit	$3M	$90,000	+3462.2%
Operating Income	-$4M	-$7M	+45.9%
Net Income	-$4M	-$8M	+43.3%

Revenue Segments

Lab Essentials

$8M79%

Clinical Solutions

$2M16%

Other Product

$440,0004%

Geographic Segments

UNITED STATES

$10M94%

Non-US

$622,0006%